Tumor-derived Tissue Factor-bearing Microparticles Are Associated with Venous Thromboembolic Events in Malignancy

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2009 Oct 29

PMID 19861441

Citations 176

Authors

Jeffrey I Zwicker

Howard A Liebman

Donna Neuberg

Romaric Lacroix

Kenneth A Bauer

Barbara C Furie

Bruce Furie

Affiliations

Soon will be listed here.

Abstract

Purpose: Despite the strong association between malignant disease and thromboembolic disorders, the molecular and cellular basis of this relationship remains uncertain. We evaluated the hypothesis that tumor-derived tissue factor-bearing microparticles in plasma contribute to cancer-associated thrombosis.

Experimental Design: We developed impedance-based flow cytometry to detect, quantitate, and size microparticles in platelet-poor plasma. We evaluated the number of tissue factor-bearing microparticles in a cohort of cancer patients of different histologies (N = 96) and conducted a case-control study of 30 cancer patients diagnosed with an acute venous thromboembolic event (VTE) compared with 60 cancer patients of similar age, stage, sex, and diagnosis without known VTE, as well as 22 patients with an idiopathic VTE.

Results: Tissue factor-bearing microparticles were detected in patients with advanced malignancy, including two thirds of patients with pancreatic carcinoma. Elevated levels of tissue factor-bearing microparticles were associated VTE in cancer patients (adjusted odds ratio, 3.72; 95% confidence interval, 1.18-11.76; P = 0.01). In cancer patients without VTE, a retrospective analysis revealed a 1-year cumulative incidence of VTE of 34.8% in patients with tissue factor-bearing microparticles versus 0% in those without detectable tissue factor-bearing microparticles (Gray test P = 0.002).The median number of tissue factor-bearing microparticles in the cancer VTE cohort (7.1 x 10(4) microparticles/microL) was significantly greater than both the idiopathic VTE and cancer-no VTE groups (P = 0.002 and P = 0.03, respectively). Pancreatectomy in three patients eliminated or nearly eliminated these microparticles which coexpressed the epithelial tumor antigen, MUC-1.

Conclusion: We conclude that tumor-derived tissue factor-bearing microparticles are associated with VTE in cancer patients and may be central to the pathogenesis of cancer-associated thrombosis.

Citing Articles

Circulating, Extracellular Vesicle-Associated Tissue Factor in Cancer Patients with and without Venous Thromboembolism.

Lami V, Nieri D, Pagnini M, Gattini M, Donati C, De Santis M Biomolecules. 2025; 15(1.

PMID: 39858477 PMC: 11762650. DOI: 10.3390/biom15010083.

Assessing the Comparative Efficacy and Safety of Warfarin and Rivaroxaban for Cancer Associated Thrombosis: Experience From a Resource Limited Setting.

Tasamma A, Bukate T, Mehadi A, Handiso B, Kassa B, Hassen E Cancer Rep (Hoboken). 2025; 8(1):e70105.

PMID: 39846434 PMC: 11755349. DOI: 10.1002/cnr2.70105.

The theragnostic advances of exosomes in managing leukaemia.

Ghosh S, Dey A, Chakrabarti A, Bhuniya T, Indu N, Hait A J Cell Mol Med. 2024; 28(23):e70052.

PMID: 39659020 PMC: 11632122. DOI: 10.1111/jcmm.70052.

Management of anticoagulation in patients with brain metastasis.

Hamulyak E, Yust-Katz S, Leader A Hematology Am Soc Hematol Educ Program. 2024; 2024(1):246-252.

PMID: 39644055 PMC: 11665513. DOI: 10.1182/hematology.2024000660.

How I treat acute venous thromboembolism in patients with brain tumors.

Leader A, Wilcox J, Zwicker J Blood. 2024; 144(17):1781-1790.

PMID: 39197077 PMC: 11530362. DOI: 10.1182/blood.2023023450.

References

Chironi G, Simon A, Hugel B, Del Pino M, Gariepy J, Freyssinet J . Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol. 2006; 26(12):2775-80. DOI: 10.1161/01.ATV.0000249639.36915.04. View

Donati M . Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. Thromb Haemost. 1995; 74(1):278-81. View

Hercher M, Mueller W, Shapiro H . Detection and discrimination of individual viruses by flow cytometry. J Histochem Cytochem. 1979; 27(1):350-2. DOI: 10.1177/27.1.374599. View

Levitan N, Dowlati A, Remick S, Tahsildar H, Sivinski L, Beyth R . Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999; 78(5):285-91. DOI: 10.1097/00005792-199909000-00001. View

Shet A, Aras O, Gupta K, Hass M, Rausch D, Saba N . Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood. 2003; 102(7):2678-83. DOI: 10.1182/blood-2003-03-0693. View

Khorana A, Fine R . Pancreatic cancer and thromboembolic disease. Lancet Oncol. 2004; 5(11):655-63. DOI: 10.1016/S1470-2045(04)01606-7. View

Boccaccio C, Sabatino G, Medico E, Girolami F, Follenzi A, Reato G . The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature. 2005; 434(7031):396-400. DOI: 10.1038/nature03357. View

Levi E, Klimstra D, Andea A, Basturk O, Adsay N . MUC1 and MUC2 in pancreatic neoplasia. J Clin Pathol. 2004; 57(5):456-62. PMC: 1770304. DOI: 10.1136/jcp.2003.013292. View

Khorana A, Ahrendt S, Ryan C, Francis C, Hruban R, Hu Y . Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007; 13(10):2870-5. DOI: 10.1158/1078-0432.CCR-06-2351. View

10.

Jimenez J, Jy W, Mauro L, Horstman L, Ahn Y . Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease. Br J Haematol. 2001; 112(1):81-90. DOI: 10.1046/j.1365-2141.2001.02516.x. View

11.

Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D . Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol. 2005; 23(18):4063-9. DOI: 10.1200/JCO.2005.10.192. View

12.

Nand S, Fisher S, Salgia R, Fisher R . Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. J Clin Oncol. 1987; 5(12):1998-2003. DOI: 10.1200/JCO.1987.5.12.1998. View

13.

Johnson M, Walker I, Sproule M, Conkie J . Abnormal coagulation and deep venous thrombosis in patients with advanced cancer. Clin Lab Haematol. 1999; 21(1):51-4. DOI: 10.1046/j.1365-2257.1999.00163.x. View

14.

Buccheri G, Ferrigno D, Ginardi C, Zuliani C . Haemostatic abnormalities in lung cancer: prognostic implications. Eur J Cancer. 1997; 33(1):50-5. DOI: 10.1016/s0959-8049(96)00310-3. View

15.

Arkel Y . Thrombosis and cancer. Semin Oncol. 2000; 27(3):362-74. View

16.

Furie B, Furie B . Mechanisms of thrombus formation. N Engl J Med. 2008; 359(9):938-49. DOI: 10.1056/NEJMra0801082. View

17.

Callander N, Varki N, Rao L . Immunohistochemical identification of tissue factor in solid tumors. Cancer. 1992; 70(5):1194-201. DOI: 10.1002/1097-0142(19920901)70:5<1194::aid-cncr2820700528>3.0.co;2-e. View

18.

Sallah S, Husain A, Sigounas V, Wan J, Turturro F, Sigounas G . Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res. 2004; 10(21):7238-43. DOI: 10.1158/1078-0432.CCR-04-0445. View

19.

Khorana A, Francis C, Menzies K, Wang J, Hyrien O, Hathcock J . Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost. 2008; 6(11):1983-5. PMC: 2848502. DOI: 10.1111/j.1538-7836.2008.03156.x. View

20.

Ho S, Niehans G, Lyftogt C, Yan P, Cherwitz D, Gum E . Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 1993; 53(3):641-51. View